GLP-1 weight-loss drugs reshape U.S. cannabis sales and retail strategy

The booming appetite-suppressing class of GLP-1 weight-loss drugs is starting to change what cannabis customers want, and dispensaries are responding by reshaping shelves built around impulse buys, snacks and high-volume edibles. In a $40 billion U.S. cannabis market, that shift matters because the old retail playbook depended on craving, indulgence and the classic munchies.

Retailers and industry executives are now adjusting product offerings to fit a consumer base whose eating patterns are changing under therapies that blunt appetite. That means more attention to lower-dose products, wellness-oriented items and formats that do not lean on the food-driven buying habits that helped fuel edibles and cannabis beverages. The concern is not that demand has collapsed, but that the customer is changing faster than many stores are built to serve.

The consumer behavior shift is already showing up online. Users on forums have said they felt diminished cravings after starting GLP-1 drugs, along with uncertainty about whether they wanted cannabis in the same way as before. That sentiment is important for retailers because cannabis sales have long depended on repeat purchasing patterns tied to recreation, routine and add-on purchases at the counter.

The medical backdrop is intensifying the trend. The U.S. Food and Drug Administration approved a higher-dose Wegovy injection in March 2026, and Novo Nordisk said in December 2025 that the agency had approved a once-daily oral Wegovy pill for weight loss, expanding access beyond injections. As GLP-1 drugs reach more patients, merchants in adjacent consumer categories are treating them as a planning issue, not just a pharmaceutical story.

The scientific context points in the same direction. A 2024 Molecular Psychiatry study found an association between semaglutide use and reduced incidence and relapse of cannabis use disorder. The paper said cannabis is the most frequently used illicit drug in the United States, with more than 45 million users, and noted there are no FDA-approved medications for cannabis use disorder. The study does not prove causation, but it adds weight to the idea that GLP-1 drugs may be affecting reward pathways that reach beyond food.

PwC has said GLP-1-driven behavior changes are already affecting food, beverage, retail, travel and entertainment. Cannabis is now part of that wider adjustment. For dispensaries, the message is clear: the next phase of growth may depend less on oversized edibles and more on products and merchandising built for a more health-conscious, less snack-driven customer.